News | September 08, 2014

MedStar Georgetown University Hospital to bring first proton therapy center to Washington, D.C.

MedStar Georgetown to Install Mevion S250 Proton Therapy System to Treat Adult and Pediatric Cancer Patients

September 8, 2014 — Mevion Medical Systems announced that MedStar Georgetown University Hospital has received final approval to begin construction of the first proton therapy center in Washington, D.C., at its Lombardi Comprehensive Cancer Center.

Georgetown Lombardi is the only cancer center in the D.C. area to earn the National Cancer Institute (NCI) designation as a comprehensive cancer center. The Mevion S250, the world’s smallest single-room proton therapy system, delivers the same precise, noninvasive treatment advantages and capabilities of larger, more expensive proton therapy systems but with a significantly reduced footprint, improved reliability, more efficient patient access, and dramatically lower implementation and operational costs.

Proton therapy is an advanced form of external radiation treatment that aims a powerful beam of protons at a tumor with incredible accuracy. Because of the special properties of protons, treatments result in less damage to surrounding healthy tissue and a reduced risk of secondary malignancies. Proton therapy is commonly used to treat a wide range of cancers in sensitive locations, such as the central nervous system, chest, head and neck, eye, and prostate. This advanced form of radiation is extremely valuable for the treatment of cancer in pediatric patients, who can be more prone to complications from radiation treatment.

Construction is scheduled to start in the fall, with installation of the Mevion S250 to be complete in 2016.

“The addition of proton therapy to our experienced and internationally known cancer program is a natural progression for us as the only provider in the region with a long history of serving both children as well as adults with cancer,” said Richard Goldberg, M.D., president, MedStar Georgetown University Hospital. “We are excited to bring this important technology to our community and to give our patients yet another cutting-edge cancer treatment option.”

“The Mevion S250 proton therapy system provides a significant benefit to cancer patients while redefining the economics and accessibility of proton therapy,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems. “We are proud to bring the most advanced radiation therapy device to our nation’s capital and another leading healthcare institution.”

For more information: www.mevion.com, www.lombardi.georgetown.edu


Related Content

News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
Subscribe Now